| 查看: 532 | 回复: 3 | |||
[交流]
西替利嗪在儿童用药的主要风险是什么?
|
|
西替利嗪用于儿童,不同资料说法不一:包括“不推荐用于6岁以下儿童”,“不推荐用于12岁以下儿童”,“2岁以下儿童禁用”,“可用于儿童及妊娠或哺乳的妇女”不一而足。 目前权威的说法是? 西替利嗪在儿童用药的主要风险是什么? 希望有最新资料的站友给予解释 |
» 猜你喜欢
基金申报
已经有3人回复
国自然申请面上模板最新2026版出了吗?
已经有9人回复
溴的反应液脱色
已经有6人回复
纳米粒子粒径的测量
已经有7人回复
常年博士招收(双一流,工科)
已经有4人回复
推荐一本书
已经有10人回复
参与限项
已经有5人回复
有没有人能给点建议
已经有5人回复
假如你的研究生提出不合理要求
已经有12人回复
萌生出自己或许不适合搞科研的想法,现在跑or等等看?
已经有4人回复
» 本主题相关价值贴推荐,对您同样有帮助:
转:用创新承载梦想--扬子江药业致力新品名品开发研制巡礼
已经有15人回复
【转帖】强生制药双阴影:召回局未了,质量门添忧
已经有0人回复
» 抢金币啦!回帖就可以得到:
散金
+5/600
南京大学能源与资源学院-景旭东教授 (英国皇家工程院院士) 团队博士后招聘
+1/477
限广州,征女友
+2/180
持续创业者,A8离异男征婚,事业遇到瓶颈,寻找创业生活伴侣
+1/164
哈尔滨工业大学王东博课题组/中科院上海微系统所梁丽娟课题组招收2026年博士生1名
+1/86
这个有点难
+1/80
真诚找对象
+1/57
香港理工大学招收电力系统优化及运筹学博士后
+1/56
Win10系统Xshell窗口小、无法移动、不显示工具栏的一个解决办法
+1/38
智合健物课题组2026年博士生招生(湖北工业大学)
+1/37
墨子实验室理论模拟研究组诚聘海内外优秀人才
+1/25
北京化工大学化学工程学院杨琪教授 邱介山教授,招收储能电池方向博士研究生
+1/24
电子科技大学「基础与前沿研究院」文明健老师课题组招收博士
+1/16
南京邮电大学-材料院尹超教授课题组-诚聘材料、化学、生物医学博士后(长期有效)
+1/12
香港浸会大学化学系质谱分析测试中心招聘研究助理
+1/10
[请教]审稿意见回复
+1/6
中国科学院大学-杨晗课题组-诚聘-博士后、副研究员
+1/4
香港中文大学(深圳)管君课题组 微纳光学方向 招收硕士、博士、博士后
+1/3
澳门科技大学诚招2026年秋季生物材料/药物递送方向博士研究生(全奖)
+1/3
寻找part-time或full time的药品注册工作
+1/2
2楼2011-07-13 14:49:57
3楼2011-07-13 21:28:14
★
qinhy(金币+1): 谢谢回帖交流~ 2011-07-14 17:55:39
qinhy(金币+1): 谢谢回帖交流~ 2011-07-14 17:55:39
|
以下是国外网站的资料,显示对6个月以上儿童进行过安全性评价,应该可以使用。 国外上市的有片剂、糖浆剂和咀嚼片。 ZYRTEC (cetirizine) can be taken without regard to food consumption. ZYRTEC (cetirizine) is available as 5 mg and 10 mg tablets, 1 mg/mL syrup, and 5 mg and 10 mg chewable tablets which can be taken with or without water. Adults and Children 12 Years and Older: The recommended initial dose of ZYRTEC (cetirizine) is 5 mg or 10 mg per day in adults and children 12 years and older, depending on symptom severity. Most patients in clinical trials started at 10 mg. ZYRTEC (cetirizine) is given as a single daily dose. The time of administration may be varied to suit individual patient needs. Children 6 to 11 Years: The recommended initial dose of ZYRTEC (cetirizine) in children aged 6 to 11 years is 5 mg or 10 mg once daily depending on symptom severity. The time of administration may be varied to suit individual patient needs. Children 2 to 5 Years: The recommended initial dose of ZYRTEC (cetirizine) in children aged 2 to 5 years is 2.5 mg (? teaspoon) syrup once daily. The dosage in this age group can be increased to a maximum dose of 5 mg per day given as 1 teaspoon syrup once a day or one ? teaspoon syrup given every 12 hours, or one 5 mg chewable tablet once a day. Children 6 months to <2 years: The recommended dose of ZYRTEC (cetirizine) syrup in children 6 months to 23 months of age is 2.5 mg (? teaspoon) once daily. The dose in children 12 to 23 months of age can be increased to a maximum dose of 5 mg per day, given as ? teaspoon (2.5 mg) every 12 hours. Syrup is recommended for children under the age of 2 years. Pediatric Use: The safety of ZYRTEC (cetirizine) has been demonstrated in pediatric patients aged 6 months to 11 years. The safety of ZYRTEC (cetirizine) , at daily doses of 5 or 10 mg, has been demonstrated in 376 pediatric patients aged 6 to 11 years in placebo-controlled trials lasting up to four weeks and in 254 patients in a non-placebo-controlled 12-week trial. The safety of cetirizine has been demonstrated in 168 patients aged 2 to 5 years in placebo-controlled trials of up to 4 weeks duration. On a mg/kg basis, most of the 168 patients received between 0.2 and 0.4 mg/kg of cetirizine HCl. The safety of cetirizine in 399 patients aged 12 to 24 months has been demonstrated in a placebo-controlled 18-month trial, in which the average dose was 0.25 mg/kg bid, corresponding to a range of 4 to 11 mg/day. The safety of ZYRTEC (cetirizine) syrup has been demonstrated in 42 patients aged 6 to 11 months in a placebo-controlled 7-day trial. The prescribed dose was 0.25 mg/kg bid, which corresponded to a mean of 4.5 mg/day, with a range of 3.4 to 6.2 mg/day. The effectiveness of ZYRTEC (cetirizine) for the treatment of allergic rhinitis and chronic idiopathic urticaria in pediatric patients aged 6 months to 11 years is based on an extrapolation of the demonstrated efficacy of ZYRTEC (cetirizine) in adults with these conditions and the likelihood that the disease course, pathophysiology and the drug's effect are substantially similar between these two populations. Efficacy is extrapolated down to 6 months of age for perennial allergic rhinitis and down to 2 years of age for seasonal allergic rhinitis because these diseases are thought to occur down to these ages in children. The recommended doses for the pediatric population are based on cross-study comparisons of the pharmacokinetics and pharmacodynamics of cetirizine in adult and pediatric subjects and on the safety profile of cetirizine in both adult and pediatric patients at doses equal to or higher than the recommended doses. The cetirizine AUC and Cmax in pediatric subjects aged 6 to 23 months who received a mean of 2.3 mg in a single dose, and in subjects aged 2 to 5 years who received a single dose of 5 mg of cetirizine syrup and in pediatric subjects aged 6 to 11 years who received a single dose of 10 mg of cetirizine syrup were estimated to be intermediate between that observed in adults who received a single dose of 10 mg of cetirizine tablets and those who received a single dose of 20 mg of cetirizine tablets. The safety and effectiveness of cetirizine in pediatric patients under the age of 6 months have not been established. Last reviewed on RxList: 5/17/2007 This monograph has been modified to include the generic and brand name in many instances. 别人的回复,贴到这,与同道共享 |
4楼2011-07-14 10:35:31












回复此楼